What was announced
AstraZeneca PLC published its results for the nine months and third quarter to 30 September 2026 on 30 October 2026. (LSE:AZN) The company described the period as one of "continued strong commercial performance and 12 positive Phase III programme readouts in the year to date". It reconfirmed its full-year 2026 guidance at constant exchange rates (CER). For total revenue, it continues to expect growth by a mid-to-high single-digit percentage. For Core EPS, it expects growth by a low double-digit percentage. The Core tax rate is expected to be between 18% and 22%.
Chief Executive Pascal Soriot said the group is "on track to deliver our 2030 ambition and to sustain growth through the next decade". (LSE:AZN) He added that "Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars." He also pointed to four new medicine approvals and 12 positive Phase III readouts, which together carry a combined peak-year Revenue potential that the company put at well above $10bn.
The numbers
For the third quarter, total revenue was $16,209m, up 7% on both a reported basis and at CER. (LSE:AZN) Product revenue was $16,173m. Core operating profit rose 17% reported and 20% at CER to $5,855m, and the Core gross Margin was 82%, up one percentage point at CER. Reported EPS rose 23% to $2.02, or 26% at CER. Core EPS was $2.79, up 17% reported and 19% at CER.
Over nine months, total revenue reached $46,881m, up 8% reported and 7% at CER. (LSE:AZN) Alliance revenue rose 33% to $2,806m. Reported EPS for the period was $5.62, up 10%, and Core EPS was $8.00, up 14% at both actual and constant rates. Core measures exclude items such as Amortisation of intangibles, impairments, legal settlements and restructuring charges. The company said that if exchange rates for October to December 2026 stay at September 2026 average levels, full-year revenue would get a low single-digit positive currency benefit, and Core EPS growth would be broadly similar to the CER figure. The release did not set out a Dividend declaration for the quarter.
Pipeline, approvals and corporate activity
AstraZeneca reported 47 approvals in major regions since its fourth-quarter 2025 results. These include first approvals for four new medicines: Etcamah, Baxfendy, Klygefa (gefurulimab) and Amlypave (anselamimab). Imfinzi received US Priority Review for the VOLGA trial. Positive Phase III readouts included Enhertu in DESTINY-Lung04, tozorakimab in the OBERON and TITANIA COPD trials, and Tezspire in CROSSING. The group also disclosed setbacks. SERENA-4 for Etcamah and CARDIO-TTRansform for Wainua did not meet their primary endpoints. The volrustomig eVOLVE-Lung02 trial was stopped for futility, and the Ultomiris AWAKE trial was discontinued for lack of efficacy. The EU application for Truqap based on CAPItello-281 was withdrawn.
On the corporate side, AstraZeneca completed a $2bn Equity Investment in Summit Therapeutics, giving it rights equivalent to about 12.0% of outstanding common stock, and agreed clinical collaborations with Summit. It also entered a discovery deal with insitro covering MASH and cardiomyopathies, with $40m upfront and up to about $1.46bn in milestones. It set out a three-year Reshaping for Sustainable Growth programme. The programme carries up to $2.0bn of one-time costs and is expected to deliver $1.5bn of annualised pre-tax savings, mainly reinvested in the pipeline, and to be substantially complete by the end of 2029.
What to watch next
The company held a conference call and webcast at 14:30 UK time on 30 October 2026. Its full-year and fourth-quarter 2026 results are scheduled for 9 February 2027. Key points to monitor include delivery against the reconfirmed CER guidance, regulatory progress for tozorakimab and efzimfotase alfa, and the 2027 readouts that management highlighted.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...